BRD4 and acute myeloid leukemia: Lu et al. have reported on a dual degrader of BRD4 and PLK1 utilizing CRBN, which are both considered promising therapeutic targets for AML, HBL-4 (compound 42) (Figure 10D), based on the dual-target inhibitor BI2536 126.